anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Inositol for subfertile women with polycystic ovary syndrome
1. Adult 19-44 years 2. Subfertility 3. Young Adult 19-24 years 4. Polycystic Ovarian Syndrome
Provide patient population that should be included in the study
Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
1. Adult 19-44 years 2. Uterine Fibroids Affecting Pregnancy 3. Uterus Subseptus 4. Subfertility 5. Young Adult 19-24 years 6. Bicornuate Uterus 7. Uterine Structure And Position Disorders 8. Congenital Uterine Anomaly 9. Adhesion 10. Polyp
Provide patient population that should be included in the study
Penile rehabilitation for postprostatectomy erectile dysfunction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Radical Prostatectomy 5. Young Adult 19-24 years 6. Prostate Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
1. Adult 19-44 years 2. Subfertility 3. In Vitro Fertilization 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Vasodilators for women undergoing fertility treatment
1. Adult 19-44 years 2. Subfertility 3. Ovulation Induction 4. In Vitro Fertilization 5. Young Adult 19-24 years 6. Direct Injection Of Sperm Into Cytoplasm Of The Oocyte
Provide patient population that should be included in the study
Pain relief for women undergoing oocyte retrieval for assisted reproduction
1. Adult 19-44 years 2. In Vitro Fertilization 3. Young Adult 19-24 years
Provide patient population that should be included in the study
Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer)
1. Female Infertility 2. Adult 19-44 years 3. Frozen Embryo Transfer 4. In Vitro Fertilization 5. Embryo Transfer 6. Young Adult 19-24 years
Provide patient population that should be included in the study
Anti‐adhesion therapy following operative hysteroscopy for treatment of female subfertility
1. Adult 19-44 years 2. Hysteroscopy 3. Middle Aged 45-64 years 4. Subfertility 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Young Adult 19-24 years 6. Ovarian Hyperstimulation
Provide patient population that should be included in the study
Pain relief for outpatient hysteroscopy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Diagnostic Hysteroscopy 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Cycle regimens for frozen‐thawed embryo transfer
1. Adult 19-44 years 2. Frozen Embryo Transfer 3. Middle Aged 45-64 years 4. Subfertility
Provide patient population that should be included in the study
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Young Adult 19-24 years 5. Direct Injection Of Sperm Into Cytoplasm Of The Oocyte 6. Fertilization In Vivo
Provide patient population that should be included in the study
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Superovulation 6. Young Adult 19-24 years
Provide patient population that should be included in the study
Septum resection for women of reproductive age with a septate uterus
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Young Adult 19-24 years 5. Uterus Bilocularis
Provide patient population that should be included in the study
Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Young Adult 19-24 years 5. Polycystic Ovarian Syndrome
Provide patient population that should be included in the study
Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. In Vitro Maturation 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Aspirin for in vitro fertilisation
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. In Vitro Fertilization 4. Young Adult 19-24 years 5. Direct Injection Of Sperm Into Cytoplasm Of The Oocyte
Provide patient population that should be included in the study
Volume expanders for the prevention of ovarian hyperstimulation syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Young Adult 19-24 years 5. Ovarian Hyperstimulation
Provide patient population that should be included in the study
Progestin‐only contraceptives: effects on weight
1. Adult 19-44 years 2. Young Adult 19-24 years 3. Contraception 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Hormonal contraceptives for contraception in overweight or obese women
1. Adult 19-44 years 2. Obesity 3. Middle Aged 45-64 years 4. Body Mass Index 30+ - Obesity 5. Body Mass Index 25-29 - Overweight 6. Young Adult 19-24 years 7. Adolescent 13-18 years 8. Overweight
Provide patient population that should be included in the study
Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles
1. Adult 19-44 years 2. Ooctye maturation triggering 3. Middle Aged 45-64 years 4. Subfertility 5. In Vitro Fertilization 6. Young Adult 19-24 years 7. Direct Injection Of Sperm Into Cytoplasm Of The Oocyte
Provide patient population that should be included in the study
Psychological and educational interventions for subfertile men and women
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Ovulation Induction 5. In Vitro Fertilization 6. Young Adult 19-24 years
Provide patient population that should be included in the study
Brief educational strategies for improving contraception use in young people
1. Young Adult 19-24 years 2. Contraception 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Embryo Transfer 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Assisted reproductive technologies for male subfertility
1. Oligoasthenoteratozoospermia 2. Adult 19-44 years 3. Teratozoospermia 4. Middle Aged 45-64 years 5. Subfertility 6. Young Adult 19-24 years 7. Asthenozoospermia
Provide patient population that should be included in the study
Culture media for human pre‐implantation embryos in assisted reproductive technology cycles
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Lactational amenorrhoea method for family planning
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Term Pregnancy Delivered 4. Sexually Active 5. Normal Breast Feeding 6. Lactational Amenorrhea 7. Young Adult 19-24 years 8. Healthy 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Pain relief in hysterosalpingography
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Young Adult 19-24 years 5. Hysterosalpingography
Provide patient population that should be included in the study
Luteal phase support for assisted reproduction cycles
1. Adult 19-44 years 2. Luteal Phase Defect 3. Fertility Problem 4. Subfertility 5. In Vitro Fertilization 6. Young Adult 19-24 years 7. Direct Injection Of Sperm Into Cytoplasm Of The Oocyte 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. In Vitro Fertilization 4. Cyst Of Ovary 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Subfertility 5. In Vitro Fertilization 6. Intracytoplasmic sperm injection 7. Young Adult 19-24 years 8. Aged 65-79 years
Provide patient population that should be included in the study
Vitrification versus slow freezing for women undergoing oocyte cryopreservation
1. Adult 19-44 years 2. Young Adult 19-24 years
Provide patient population that should be included in the study
Surgical intervention versus expectant management for endometrial polyps in subfertile women
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Infertility 4. Young Adult 19-24 years 5. Uterine polyp
Provide patient population that should be included in the study
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Healthy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral contraceptives for functional ovarian cysts
1. Adult 19-44 years 2. Functional Cyst Of Ovary 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Combination contraceptives: effects on weight
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Heparin for assisted reproduction
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Adolescent 13-18 years 5. Assisted reproductive techniques
Provide patient population that should be included in the study
Exercise as adjunctive therapy for systemic lupus erythematosus
1. Aged 80 and over 80+ years 2. Systemic Lupus Erythematosus 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Hip Osteoarthritis 7. Knee osteoarthritis
Provide patient population that should be included in the study
Stem cell transplantation for systemic sclerosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Systemic Sclerosis 6. Aged 65-79 years
Provide patient population that should be included in the study
Dietary supplements for chronic gout
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Gout 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Autologous blood and platelet‐rich plasma injection therapy for lateral elbow pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pain In Elbow 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Colchicine for acute gout
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Gout 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Tramadol for osteoarthritis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Osteoarthritis 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Rheumatoid Arthritis 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Methotrexate for psoriatic arthritis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Psoriatic Arthritis 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for rheumatoid arthritis of the hand
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Rheumatoid Arthritis - Hand Joint
Provide patient population that should be included in the study
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Knee Pain 4. Hip Pain 5. Aged 65-79 years 6. Hip Osteoarthritis
Provide patient population that should be included in the study
Surgery for trigger finger
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Stenosing Tenosynovitis 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Back Schools for chronic non‐specific low back pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Low Back Pain 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Celecoxib for rheumatoid arthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Rheumatoid Arthritis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Celecoxib for osteoarthritis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hip Osteoarthritis 11. Knee osteoarthritis 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for hand osteoarthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Generalized Osteoarthritis Of The Hand 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Stretch for the treatment and prevention of contractures
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Muscle Contracture 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgical options for lumbar spinal stenosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Degenerative Lumbar Spinal Stenosis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Bioabsorbable versus metallic interference screws for graft fixation in anterior cruciate ligament reconstruction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Anterior Cruciate Ligament Tear 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Electrotherapy modalities for rotator cuff disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Disorder Of Rotator Cuff 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Biologic interventions for fatigue in rheumatoid arthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Rheumatoid Arthritis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory drugs for chronic low back pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Low Back Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery for Dupuytren's contracture of the fingers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Dupuytren's Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Hip Osteoarthritis 7. Knee osteoarthritis
Provide patient population that should be included in the study
Radiofrequency denervation for chronic low back pain
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Low Back Pain
Provide patient population that should be included in the study
Intra‐articular corticosteroid for knee osteoarthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Knee osteoarthritis
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non‐radiographic axial spondyloarthritis)
1. Aged 80 and over 80+ years 2. Ankylosing Spondylitis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Non-radiographic Axial Spondylitis 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
TNF‐alpha inhibitors for ankylosing spondylitis
1. Aged 80 and over 80+ years 2. Ankylosing Spondylitis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Mobile bearing vs fixed bearing prostheses for posterior cruciate retaining total knee arthroplasty for postoperative functional status in patients with osteoarthritis and rheumatoid arthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Total knee arthroplasty 4. Middle Aged 45-64 years 5. Rheumatoid Arthritis 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Knee osteoarthritis
Provide patient population that should be included in the study
Rituximab for rheumatoid arthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Rheumatoid Arthritis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for osteoarthritis of the knee
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Knee osteoarthritis
Provide patient population that should be included in the study
Sulfasalazine for ankylosing spondylitis
1. Aged 80 and over 80+ years 2. Ankylosing Spondylitis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Uricosuric medications for chronic gout
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Gout 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Electrotherapy modalities for adhesive capsulitis (frozen shoulder)
1. Adult 19-44 years 2. Adhesive Capsulitis 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Interleukin‐1 inhibitors for acute gout
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Gout 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Manual therapy and exercise for adhesive capsulitis (frozen shoulder)
1. Adult 19-44 years 2. Adhesive Capsulitis 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Diacerein for osteoarthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Osteoarthritis 6. Aged 65-79 years
Provide patient population that should be included in the study
Self‐management education programmes for osteoarthritis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Osteoarthritis 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Rehabilitation following surgery for lumbar spinal stenosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Decompression Of Spinal Cord 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Lumbar Spinal Stenosis
Provide patient population that should be included in the study
Lifestyle interventions for acute gout
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Gout 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Non‐pharmacological interventions for fatigue in rheumatoid arthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Rheumatoid Arthritis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Rheumatoid Arthritis 5. Anemia 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatments for alopecia areata: a network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Alopecia universalis 7. Alopecia Areata 8. Young Adult 19-24 years 9. Alopecia Totalis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Psoriasis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Negative pressure wound therapy for treating pressure ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pressure ulcer 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Silicone gel sheeting for treating keloid scars
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Keloid Scar 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal sinus
1. Pilonidal Sinus Disease 2. Open Wound
Provide patient population that should be included in the study
Pressure redistributing static chairs for preventing pressure ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Sedentary 6. Aged 65-79 years
Provide patient population that should be included in the study
Silicone gel sheeting for treating hypertrophic scars
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hypertrophic Scar 6. Aged 65-79 years
Provide patient population that should be included in the study
Botulinum toxin type A for facial wrinkles
1. Aged 80 and over 80+ years 2. Crow's Feet 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Wrinkled Face 7. Rhytide Of Forehead 8. Aged 65-79 years 9. Rhytide Of Glabellar Skin 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical benzoyl peroxide for acne
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Acne 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for chronic palmoplantar pustulosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Palmoplantar Pustulosis 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical and device‐based treatments for fungal infections of the toenails
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Onychomycosis of toenails 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Lifestyle changes for treating psoriasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Psoriasis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for hand eczema
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Atopic Dermatitis Of Hands 10. Hand Eczema 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Acute Guttate Psoriasis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antistreptococcal interventions for guttate and chronic plaque psoriasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Plaque Psoriasis 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Guttate Psoriasis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Risk assessment tools for the prevention of pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Support surfaces for treating pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Education of healthcare professionals for preventing pressure ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Foam dressings for treating pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic antibiotics for treating malignant wounds
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Fungating Tumor 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Cancer
Provide patient population that should be included in the study
Anabolic steroids for treating pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Scalpel versus electrosurgery for major abdominal incisions
1. Aged 80 and over 80+ years 2. Abdominal surgery 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Drugs for discoid lupus erythematosus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Discoid Lupus Erythematosis 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Emollients and moisturisers for eczema
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Atopic Dermatitis 5. Infant 1 to 23 mo 6. Neurodermatitis 7. Dermatitis 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Eczema 14. Birth to 1 mo
Provide patient population that should be included in the study
Wound drainage for lower limb arterial surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Vascular Surgical Procedure On Lower Limb 6. Aged 65-79 years
Provide patient population that should be included in the study
Bed rest for pressure ulcer healing in wheelchair users
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Wheelchair Bound 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics and antiseptics for pressure ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Pressure ulcer 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Interventions for acne scars
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Hypertrophic Acne Scar 6. Acne 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Atrophic Scar
Provide patient population that should be included in the study
Antibiotics and antiseptics for surgical wounds healing by secondary intention
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgical Wound 5. Young Adult 19-24 years 6. Wound Healing by Secondary Intention 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgical hand antisepsis to reduce surgical site infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐TNF agents for paediatric psoriasis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Psoriasis 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for hidradenitis suppurativa
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Hidradenitis Suppurativa 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Wound‐care teams for preventing and treating pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral fumaric acid esters for psoriasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Psoriasis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Negative pressure wound therapy for treating surgical wounds healing by secondary intention
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgical Wound 5. Young Adult 19-24 years 6. Wound Healing by Secondary Intention 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for rosacea
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Rosacea
Provide patient population that should be included in the study
Preoperative skin antiseptics for preventing surgical wound infections after clean surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for vitiligo
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Vitiligo 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Repositioning for treating pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Negative pressure wound therapy for partial‐thickness burns
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Second-degree burn 6. Aged 65-79 years
Provide patient population that should be included in the study
Recombinant human growth hormone for treating burns and donor sites
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Burn 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Removal of nail polish and finger rings to prevent surgical infection
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Topical agents and dressings for fungating wounds
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Fungating wound 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pressure‐relieving devices for treating heel pressure ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pressure Ulcer Of Heel 6. Aged 65-79 years
Provide patient population that should be included in the study
Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Psoriasis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic prophylaxis for preventing burn wound infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Burn 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low‐ and middle‐income countries
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Alcohol use disorder 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Baclofen for alcohol use disorder
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Alcoholism 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioid agonist treatment for people who are dependent on pharmaceutical opioids
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Misuse Of Prescription Only Drugs 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Opioid Dependence 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Music therapy for people with substance use disorders
1. Substance use disorder
Provide patient population that should be included in the study
Strategies to improve smoking cessation rates in primary care
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Interventions to reduce tobacco use in people experiencing homelessness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Homeless 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Opioid Dependence 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Chronic Inflammatory Disorder 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive‐behavioural treatment for amphetamine‐type stimulants (ATS)‐use disorders
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Amphetamine Dependence 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antidepressants for the treatment of people with co‐occurring depression and alcohol dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Alcoholism 5. Young Adult 19-24 years 6. Depression 7. Aged 65-79 years
Provide patient population that should be included in the study
Effectiveness of brief alcohol interventions in primary care populations
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Excessive Drinking 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community‐dwelling populations
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Problem Drinker 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioid antagonists with minimal sedation for opioid withdrawal
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Opioid Withdrawal 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Supervised dosing with a long‐acting opioid medication in the management of opioid dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Opioid Dependence 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychostimulant drugs for cocaine dependence
1. Adult 19-44 years 2. Cocaine Dependence 3. Middle Aged 45-64 years 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Psychosocial interventions for cannabis use disorder
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cannabis Abuse 6. Cannabis Dependence 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Alpha2‐adrenergic agonists for the management of opioid withdrawal
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Birth to 1 mo 8. Opioid Dependence 9. Opioid Withdrawal 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antipsychotic medications for cocaine dependence
1. Adult 19-44 years 2. Cocaine Dependence 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Dopamine agonists for the treatment of cocaine dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cocaine Dependence 4. Middle Aged 45-64 years 5. Cocaine Misuse 6. Young Adult 19-24 years 7. Cocaine Abuse 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Anticonvulsants for cocaine dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cocaine Dependence 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Universal school‐based prevention for illicit drug use
1. Child 6-12 years 2. Adolescent 13-18 years
Provide patient population that should be included in the study
Restricting or banning alcohol advertising to reduce alcohol consumption in adults and adolescents
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Alcohol Intake 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Maintenance treatments for opiate ‐dependent adolescents
1. Opium Dependence 2. Adolescent 13-18 years
Provide patient population that should be included in the study
Anticonvulsants for alcohol dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Alcoholism 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Opioid Dependence 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Efficacy of psychostimulant drugs for amphetamine abuse or dependence
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Amphetamine Dependence 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Amphetamine Abuse
Provide patient population that should be included in the study
Bladder training for treating overactive bladder in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Overactive Bladder Syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women
1. Genital prolapse 2. Postmenopausal
Provide patient population that should be included in the study
Conservative interventions for managing urinary incontinence after prostate surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostatectomy 6. Urinary Incontinence 7. Aged 65-79 years
Provide patient population that should be included in the study
Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years
Provide patient population that should be included in the study
Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostatic obstruction 6. Lower urinary tract symptoms 7. Aged 65-79 years
Provide patient population that should be included in the study
Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years